Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications

Therapeutic implications

Arpeeta Sharma, Mitchel Tate, Geetha Mathew, James E. Vince, Rebecca H. Ritchie, Judy B. De Haan

Research output: Contribution to journalReview ArticleResearchpeer-review

34 Citations (Scopus)

Abstract

It is now increasingly appreciated that inflammation is not limited to the control of pathogens by the host, but rather that sterile inflammation which occurs in the absence of viral or bacterial pathogens, accompanies numerous disease states, none more so than the complications that arise as a result of hyperglycaemia. Individuals with type 1 or type 2 diabetes mellitus (T1D, T2D) are at increased risk of developing cardiac and vascular complications. Glucose and blood pressure lowering therapies have not stopped the advance of these morbidities that often lead to fatal heart attacks and/or stroke. A unifying mechanism of hyperglycemia-induced cellular damage was initially proposed to link elevated blood glucose levels with oxidative stress and the dysregulation of metabolic pathways. Pre-clinical evidence has, in most cases, supported this notion. However, therapeutic strategies to lessen oxidative stress in clinical trials has not proved efficacious, most likely due to indiscriminate targeting by antioxidants such as vitamins. Recent evidence now suggests that oxidative stress is a major driver of inflammation and vice versa, with the latest findings suggesting not only a key role for inflammatory pathways underpinning metabolic and haemodynamic dysfunction in diabetes, but furthermore that these perturbations are driven by activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. This review will address these latest findings with an aim of highlighting the interconnectivity between oxidative stress, NLRP3 activation and inflammation as it pertains to cardiac and vascular injury sustained by diabetes. Current therapeutic strategies to lessen both oxidative stress and inflammation will be emphasized. This will be placed in the context of improving the burden of these diabetic complications.

Original languageEnglish
Article number114
Number of pages15
JournalFrontiers in Physiology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - 20 Feb 2018
Externally publishedYes

Keywords

  • Diabetic atherosclerosis
  • Diabetic cardiomyopathy
  • Diabetic complications
  • Diabetic nephropathy
  • Inflammation
  • Inflammatory cytokines
  • NLRP3 inflammasome
  • Oxidative stress

Cite this

@article{46ab2985d3c5421286b50654cb1a1b6c,
title = "Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: Therapeutic implications",
abstract = "It is now increasingly appreciated that inflammation is not limited to the control of pathogens by the host, but rather that sterile inflammation which occurs in the absence of viral or bacterial pathogens, accompanies numerous disease states, none more so than the complications that arise as a result of hyperglycaemia. Individuals with type 1 or type 2 diabetes mellitus (T1D, T2D) are at increased risk of developing cardiac and vascular complications. Glucose and blood pressure lowering therapies have not stopped the advance of these morbidities that often lead to fatal heart attacks and/or stroke. A unifying mechanism of hyperglycemia-induced cellular damage was initially proposed to link elevated blood glucose levels with oxidative stress and the dysregulation of metabolic pathways. Pre-clinical evidence has, in most cases, supported this notion. However, therapeutic strategies to lessen oxidative stress in clinical trials has not proved efficacious, most likely due to indiscriminate targeting by antioxidants such as vitamins. Recent evidence now suggests that oxidative stress is a major driver of inflammation and vice versa, with the latest findings suggesting not only a key role for inflammatory pathways underpinning metabolic and haemodynamic dysfunction in diabetes, but furthermore that these perturbations are driven by activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. This review will address these latest findings with an aim of highlighting the interconnectivity between oxidative stress, NLRP3 activation and inflammation as it pertains to cardiac and vascular injury sustained by diabetes. Current therapeutic strategies to lessen both oxidative stress and inflammation will be emphasized. This will be placed in the context of improving the burden of these diabetic complications.",
keywords = "Diabetic atherosclerosis, Diabetic cardiomyopathy, Diabetic complications, Diabetic nephropathy, Inflammation, Inflammatory cytokines, NLRP3 inflammasome, Oxidative stress",
author = "Arpeeta Sharma and Mitchel Tate and Geetha Mathew and Vince, {James E.} and Ritchie, {Rebecca H.} and {De Haan}, {Judy B.}",
year = "2018",
month = "2",
day = "20",
doi = "10.3389/fphys.2018.00114",
language = "English",
volume = "9",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",
number = "FEB",

}

Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications : Therapeutic implications. / Sharma, Arpeeta; Tate, Mitchel; Mathew, Geetha; Vince, James E.; Ritchie, Rebecca H.; De Haan, Judy B.

In: Frontiers in Physiology, Vol. 9, No. FEB, 114, 20.02.2018.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications

T2 - Therapeutic implications

AU - Sharma, Arpeeta

AU - Tate, Mitchel

AU - Mathew, Geetha

AU - Vince, James E.

AU - Ritchie, Rebecca H.

AU - De Haan, Judy B.

PY - 2018/2/20

Y1 - 2018/2/20

N2 - It is now increasingly appreciated that inflammation is not limited to the control of pathogens by the host, but rather that sterile inflammation which occurs in the absence of viral or bacterial pathogens, accompanies numerous disease states, none more so than the complications that arise as a result of hyperglycaemia. Individuals with type 1 or type 2 diabetes mellitus (T1D, T2D) are at increased risk of developing cardiac and vascular complications. Glucose and blood pressure lowering therapies have not stopped the advance of these morbidities that often lead to fatal heart attacks and/or stroke. A unifying mechanism of hyperglycemia-induced cellular damage was initially proposed to link elevated blood glucose levels with oxidative stress and the dysregulation of metabolic pathways. Pre-clinical evidence has, in most cases, supported this notion. However, therapeutic strategies to lessen oxidative stress in clinical trials has not proved efficacious, most likely due to indiscriminate targeting by antioxidants such as vitamins. Recent evidence now suggests that oxidative stress is a major driver of inflammation and vice versa, with the latest findings suggesting not only a key role for inflammatory pathways underpinning metabolic and haemodynamic dysfunction in diabetes, but furthermore that these perturbations are driven by activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. This review will address these latest findings with an aim of highlighting the interconnectivity between oxidative stress, NLRP3 activation and inflammation as it pertains to cardiac and vascular injury sustained by diabetes. Current therapeutic strategies to lessen both oxidative stress and inflammation will be emphasized. This will be placed in the context of improving the burden of these diabetic complications.

AB - It is now increasingly appreciated that inflammation is not limited to the control of pathogens by the host, but rather that sterile inflammation which occurs in the absence of viral or bacterial pathogens, accompanies numerous disease states, none more so than the complications that arise as a result of hyperglycaemia. Individuals with type 1 or type 2 diabetes mellitus (T1D, T2D) are at increased risk of developing cardiac and vascular complications. Glucose and blood pressure lowering therapies have not stopped the advance of these morbidities that often lead to fatal heart attacks and/or stroke. A unifying mechanism of hyperglycemia-induced cellular damage was initially proposed to link elevated blood glucose levels with oxidative stress and the dysregulation of metabolic pathways. Pre-clinical evidence has, in most cases, supported this notion. However, therapeutic strategies to lessen oxidative stress in clinical trials has not proved efficacious, most likely due to indiscriminate targeting by antioxidants such as vitamins. Recent evidence now suggests that oxidative stress is a major driver of inflammation and vice versa, with the latest findings suggesting not only a key role for inflammatory pathways underpinning metabolic and haemodynamic dysfunction in diabetes, but furthermore that these perturbations are driven by activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome. This review will address these latest findings with an aim of highlighting the interconnectivity between oxidative stress, NLRP3 activation and inflammation as it pertains to cardiac and vascular injury sustained by diabetes. Current therapeutic strategies to lessen both oxidative stress and inflammation will be emphasized. This will be placed in the context of improving the burden of these diabetic complications.

KW - Diabetic atherosclerosis

KW - Diabetic cardiomyopathy

KW - Diabetic complications

KW - Diabetic nephropathy

KW - Inflammation

KW - Inflammatory cytokines

KW - NLRP3 inflammasome

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85042221426&partnerID=8YFLogxK

U2 - 10.3389/fphys.2018.00114

DO - 10.3389/fphys.2018.00114

M3 - Review Article

VL - 9

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

IS - FEB

M1 - 114

ER -